/Companies

Sagerx

Acquired

2 known investors

Find your way into Sagerx

Sign up to see every warm intro you have to Sagerx

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Sagerx team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Supernus is a biopharmaceutical company focused on developing and commercializing products that treat central nervous system (CNS) diseases. Following a merger of equals with Indivior and its acquisition of Sage Therapeutics, it operates as a diversified CNS biopharmaceutical company.

Also known as SAGE · Sage Therapeutics · Sage Therapeutics, Inc.

Investors · 2

Company profile

researched Aug 2026

Sage Therapeutics, Inc. (sagerx.com) is a Cambridge, Massachusetts-based biopharmaceutical company focused on central nervous system and brain health disorders, particularly at the intersection of neuroscience and women's health. The company describes its mission as delivering brain health medicines, and organizes its operations across Commercial, General & Administrative, Research & Development, and Technical Operations functions, including clinical operations, data science, regulatory, drug safety and pharmacovigilance, and end-to-end manufacturing, supply and quality oversight.

Sage's commercial history centers on postpartum depression. It brought Zulresso, described as the first approved medicine for postpartum depression, to market as a 60-hour infusion, and subsequently Zurzuvae (zuranolone), described as the first pill for the condition, developed with Biogen. Beyond these commercial efforts, the company reported a pipeline of novel neuroscience candidates targeting neuropsychiatric and neurodevelopmental disorders. Multiple experimental programs failed clinical studies in epilepsy, essential tremor, Alzheimer's, Huntington's and Parkinson's disease.

On June 16, 2025, Sage agreed to be acquired by Supernus Pharmaceuticals for $8.50 per share, a deal valued at $561 million plus a contingent value right of up to $3.50 per share tied to Zurzuvae sales milestones; one trade publication characterized the transaction as worth up to $795 million including contingent payments. Supernus's website now hosts links to Sage Therapeutics information and directs adverse event and product complaint reporting through Supernus Medical Information Support.

Founding story

Sage Therapeutics was founded in 2010 and was launched by venture firm Third Rock Ventures, with the goal of developing brain drugs across a range of conditions including epilepsy, tremors and Huntington's disease. Biotech veteran Jeff Jonas ran the company for many years.

Business model

Sage developed proprietary small-molecule therapeutics for CNS and brain health conditions and commercialized approved products directly and through partnership. Its lead marketed product, Zurzuvae (zuranolone) for postpartum depression, was developed and commercialized under a multibillion-dollar collaboration with Biogen, with U.S. profits split between the two companies. An earlier product, Zulresso, a 60-hour infusion for postpartum depression, was marketed by Sage until it was discontinued.

Revenue derived from sales of approved CNS medicines, with U.S. profits from Zurzuvae shared with development partner Biogen. Zurzuvae generated $72 million in U.S. sales in 2024.

Traction

Zurzuvae generated $72 million in U.S. sales in 2024, with profits split with Biogen. Reported total funding raised was $2.7 billion as of July 2026, with the last recorded funding event of $650 million on November 27, 2020. Headcount was approximately 201 as of July 2026, following a reduction of 338 employees effective August 1, 2025.

Latest developments

Sage agreed on June 16, 2025 to be acquired by Supernus Pharmaceuticals for $561 million ($8.50 per share) plus a contingent value right of up to $3.50 per share tied to Zurzuvae sales milestones. A WARN filing on June 26, 2025 indicated the layoff of all 338 Massachusetts employees in August 2025 pending deal closure. Supernus's corporate website now redirects Sage Therapeutics functions, including medical information and adverse event reporting, to Supernus. LeadIQ additionally reports that Sage's Chief Scientific Officer and interim Head of R&D departed on June 11, 2026. The Sage careers site remains live but lists no open positions.

▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies

Market position

Sage was characterized as a midsize biotechnology company and, before the acquisition, a publicly traded company under the ticker SAGE. An analyst described the Supernus deal as "an unremarkable outcome for a company that was once one of the hottest stories" in brain drug research, while another called the offer "fair" given the considerable time required for Sage to reach profitability. Analysts saw a very low likelihood that most of the contingent sales milestones would be met.

Sage was the developer of the first approved medicine for postpartum depression (Zulresso) and of the first oral treatment for the condition (Zurzuvae), giving it an established position in postpartum depression and broader brain health. Its portfolio and pipeline focused on neuropsychiatric and neurodevelopmental indications, including areas at the intersection of neuroscience and women's health.

Technology

Sage developed small-molecule medicines for neuropsychiatric and neurodevelopmental disorders; its marketed products are Zulresso (infusion) and Zurzuvae/zuranolone (oral) for postpartum depression. Its enterprise technology stack was reported to include Power BI, Tableau, SAP, Talend, Microsoft Visio, jQuery and Apache, along with cloud, data integration and pharmacovigilance tools such as AWS, Fivetran, Datadog and Oracle Argus.

Go-to-market

Commercial operations spanned marketing, sales, patient support and market access, including a field-based sales force organized by territory. U.S. commercialization of Zurzuvae was conducted in partnership with Biogen.

Patients with central nervous system and brain health disorders, notably women with postpartum depression, along with prescribing healthcare providers, payers and maternal health networks.

Geography

Headquartered in Massachusetts, United States (Cambridge), with employees reported across five continents including North America, Asia and Europe. The company operated a remote-flexible work model ("SageFlex") alongside field-based roles assigned to specific U.S. territories.

History

Founded in 2010 and launched by Third Rock Ventures, Sage was run for many years by biotech veteran Jeff Jonas and pursued brain drugs across epilepsy, tremors, Huntington's disease and other conditions. It went public in 2014 and its shares reached nearly $200 as two depression candidates advanced. Sage brought Zulresso, the first medicine for postpartum depression, and later Zurzuvae, the first pill for the condition, to market, and signed a multibillion-dollar partnership with Biogen. Experimental programs subsequently failed studies in epilepsy, tremors, Alzheimer's, Huntington's and Parkinson's disease. After U.S. regulators requested additional testing for Zurzuvae in major depressive disorder, the company changed course and cut staff. In 2025 Sage rejected a $7.22-per-share bid from Biogen and sued the partner over valuation, then ran a strategic alternatives process that ended with the June 16, 2025 agreement to be acquired by Supernus Pharmaceuticals. Sage filed a Massachusetts WARN notice on June 26, 2025 covering all 338 employees, with the reduction effective August 1, 2025.

Risks & controversies

Sage experienced repeated clinical setbacks, with experimental drugs failing studies in epilepsy, tremors, Alzheimer's, Huntington's and Parkinson's disease. Zulresso, requiring a 60-hour infusion, never generated significant sales and was discontinued. Regulators required additional testing before Zurzuvae could be approved for major depressive disorder, prompting a strategic shift and layoffs. Shares fell from a peak near $200 to $6.70 before the acquisition announcement. A securities fraud complaint was filed in 2025 on behalf of investors who bought shares between April 12, 2021 and July 23, 2024, and Sage sued Biogen in a dispute over an earlier takeover bid. The careers site carries a notice warning about fraudulent job postings using the Sage name.

Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Acquisition price per shareJun 2025$8.5
EmployeesJul 2026201 people
Headcount reductionAug 2025338 people
Share price at close before deal announcementJun 2025$6.7
Total funding raisedJul 2026$2.7B
Zurzuvae U.S. salesJan 2024$72M

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Related companies · 4

Companies working in the same space as Sagerx.

Timeline · 10

launches, deals, and filings
Jun 2026
Chief Scientific Officer and interim Head of R&D departs

Sage's Chief Scientific Officer and interim Head of R&D left the company on June 11, 2026.

source ↗

Jun 2025
WARN notice filed for layoff of all 338 Massachusetts employees

Sage filed a WARN notice with Massachusetts indicating it would lay off all 338 employees in August 2025 pending closing of the Supernus deal; headcount decreased by 338 on Aug 1, 2025.

source ↗

Jun 2025
Supernus Pharmaceuticals agrees to acquire Sage Therapeutics

Supernus Pharmaceuticals agreed to acquire Sage Therapeutics in a deal worth $561 million, paying $8.50 per share (about a 27% premium to the prior close), plus a contingent value right of up to $3.50 per share tied to U.S. sales and commercial milestones for Zurzuvae ($1 per share if U.S. Zurzuvae sales reach $250M by 2027, with similar payouts at $300M by 2028 and $375M by 2030). Other coverage described the transaction as worth up to $795 million.

$561M source ↗

Apr 2025
Securities fraud complaint filed against Sage

A securities fraud complaint was filed against Sage on behalf of certain investors who purchased or acquired shares between April 12, 2021 and July 23, 2024.

source ↗

Jan 2025
Sage presents 2025 Strategic Focus at J.P. Morgan Healthcare Conference

source ↗

Jan 2025
Sage rejects Biogen offer and sues partner

Sage turned down a $7.22-per-share acquisition offer from Zurzuvae development partner Biogen and sued the company, arguing it was being undervalued; Sage subsequently ran a strategic alternatives process including a search for a buyer.

source ↗

Jan 2023
Zurzuvae, first pill for postpartum depression, brought to market

Sage and partner Biogen brought Zurzuvae (zuranolone) to market as the first pill for postpartum depression; U.S. profits are split with Biogen. Plans to expand into major depressive disorder were changed after U.S. regulators asked for additional testing, followed by layoffs.

source ↗

Nov 2020
Biogen collaboration on zuranolone

Sage entered a multibillion-dollar partnership with Biogen to develop and commercialize zuranolone (Zurzuvae); LeadIQ records a $650M funding event dated Nov 27, 2020.

$650M source ↗

Jan 2019
Zulresso, first approved medicine for postpartum depression, brought to market

Sage brought to market Zulresso, the first medicine for postpartum depression, administered as a 60-hour infusion. It never generated significant sales and Sage stopped marketing it at the end of the year (2024).

source ↗

Jan 2014
Initial public offering

Sage went public in 2014 to fund development of brain drugs; shares later rose to nearly $200 apiece.

source ↗

Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.

▸Research sources · 8

primary sources listed

8 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Sagerx do?
Sage Therapeutics is a CNS-focused biopharmaceutical company, maker of Zurzuvae, acquired by Supernus Pharmaceuticals in 2025.
Who are Sagerx's investors?
Sagerx's investors include ARCH Venture Partners, EcoR1 Capital.